U.S. Serial No. 10/626,941 Response of Office Action mailed February 24, 2005 DW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANT: Manning, et al.) GROUP ART UNIT: 1614

SERIAL NO.: 10/626,941) CONFIRMATION NO.: 3233

EXAMINER: Phyllis G. Spivack) ATTORNEY DOCKET 01073/1/US

NO.:

FILED: July 25, 2003) DATE: May 24, 2005

TITLE: METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 24, 2005

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

REPLY TO OFFICE ACTION

Sir:


This letter is in response to the Office Action dated February 24, 2004. The Applicants believe that this response is timely filed, however please charge any appropriate fees to Deposit Account No 19-1025.

AMENDMENT TRANSMITTAL LETTER (Large Entity) Do						ocket No.	
Applicant(s): Manning et al.				01073/1/US			
Application No. 10/626,941	Filing Date July 25, 2003	Examiner Phyllis G. Spivack		mer No. 6648	Group Art Uni 1614	Confirmation No.	
Invention: OF GASTROINTESTINAL CONDITIONS MAY 2 6 2005 ©							
Transmitted berev	RAMAN GENT	COMMISSIONER FO	R PATENTS:		•		
Transmitted herew	vith is an amendment i	n the above-identified a	pplication.				
The fee has been	calculated and is trans	mitted as shown below.					
		CLAIMS AS AM	ENDED				
	CLAIMS REMAINING	HIGHEST #	NUMBER EXT	RA	DATE	ADDITIONAL	
	AFTER AMENDMENT	PREV. PAID FOR	CLAIMS PRESI	ENT	RATE	FEE	
TOTAL CLAIMS	43 -	43 =	0	x	\$50.00	\$0.00	
INDEP. CLAIMS	2 -	3 =	0	x	\$200.00	\$0.00	
Multiple Dependent Claims (check if applicable) □ \$0.00							
		TOTAL ADDITIONAL F	EE FOR THI	S AMEN	DMENT	\$0.00	
 No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. ☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025 ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. □ Payment by credit card. Form PTO-2038. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. 							
Dated: May 24, 2005							
Philip B. Polster, II Reg. No. 43,864 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.9094			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on May 24, 2005 (Date) Signature of Person Mailing Correspondence				

CC:

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence



TRANSMITTAL LETTER (General - Patent Pending)

Docket No. 010731/1/US

Manning et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/626,941	July 25, 2003	Phyllis G. Spivack	26648	1614	3233

METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Amendment Transmittal; Response to Office Action; Itemized Postcard.

in the above identified application.

			-		
	NIA	additional	too	ic	required
\sim	110	auullionai	100	13	reduired.

A check in the amount of

is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1025

as described below.

Charge the amount of

Credit any overpayment.

Charge any additional fee required.

☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Dated: May 24, 2005

Philip B. Polster, II Reg. 43,864 Pharmacia Corporation of Pfizer Inc.

P.O. Box 1027

Chesterfield, Missouri 63006

314.274.9094

I hereby certify that this correspondence deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

May 24, 2005

ature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence